Table 1. Characteristics of the study population.
| Control group | Patients | P-value | |
|---|---|---|---|
| n = 10 | n = 26 | ||
| Age (y) | 62 ± 11 | 68 ± 5 | 0.068 |
| Gender (f/m) | 7 / 3 | 10 / 16 | - |
| Height (cm) | 170 ± 8 | 170 ± 8 | 0.771 |
| Weight (kg) | 68 ± 9 | 77 ± 12 | 0.038 |
| Body mass index | 24 ± 2 | 26 ± 3 | 0.017 |
| HR at rest (bpm) | 72 ± 8 | 67 ± 10 | 0.321 |
| Systolic blood pressure (mmHg) | 128 ± 12 | 144 ± 11 | 0.001 |
| Diastolic blood pressure (mmHg) | 76 ± 6 | 78 ± 7 | 0.417 |
| VO2max/bw (ml/(min·kg)) | - | 22 ± 6 | - |
| MRI data | |||
| Ejection fraction (%) | 64 ± 6 | 61 ± 7 | 0.213 |
| LVEDV (ml) | 133 ± 21 | 126 ± 30 | 0.517 |
| LVEDVI (ml/m2) | 74 ± 9 | 66 ± 13 | 0.079 |
| LVESV (ml) | 48 ± 10 | 45 ± 15 | 0.548 |
| LVESVI (ml/m2) | 27 ± 5 | 23 ± 7 | 0.194 |
| LVMI (g/m2) | - | 52 ± 11 | - |
| Positive LGE (number of patients) | - | 10 | - |
| NYHA classification (number of patients) | |||
| I | - | 16 | - |
| II | - | 10 | - |
| Medication (number of patients) | |||
| Beta-blocker | 0 | 16 | - |
| ACE-I | 0 | 7 | - |
| ARB | 0 | 6 | - |
| Calcium channel blocker | 0 | 9 | - |
| Nitrate | 0 | 9 | - |
| Aspirin | 0 | 22 | - |
| Clopidogrel | 0 | 2 | - |
| Warfarin | 0 | 1 | - |
| Statin | 0 | 23 | - |
| Diuretic | 0 | 2 | - |
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; HR, heart rate; LVEDV, left ventricular end diastolic volume; LVEDVI, left ventricular end diastolic volume index; LVESV, left ventricular end systolic volume; LVESVI, left ventricular end systolic volume index; LVMI, left ventricular mass index; NYHA, New York Heart Association; Positive LGE, late gadolinium enhancement in the LV myocardium; VO2max/bw, maximal oxygen consumption/body weight.